Ginkgo Bioworks (DNA) Q4 2024 earnings summary

Executive summary

• Achieved significant cost reductions, including a $190 million annualized run rate reduction by Q4 2024 and a sharp decrease in cash burn to $55 million in Q4, with over $560 million in cash and no bank debt.

• Restructuring included a workforce reduction of over 40% and site consolidations, driving improved cash flow and narrowing losses.

• Expanded into direct sales of life science tools and services, with strong demand for Datapoints and Automation offerings.

• Maintained a pool of up to $1.7 billion in potential milestone payments from customer collaborations, though this figure decreased by $700 million year-over-year.

• Focused on reaching adjusted EBITDA break-even by end of 2026, with continued cost discipline and expansion of revenue sources.

Financial highlights

• FY 2024 total revenue was $227 million, up 16% year-over-year; Q4 2024 revenue was $44 million, with Cell Engineering revenue up 29% and Biosecurity revenue up 13%.

• Full-year 2024 Cell Engineering revenue was $174 million (up 21% year-over-year); excluding a $45 million non-cash item, $129 million (down 10%).

• Full-year 2024 Biosecurity revenue was $53 million, down 51% from 2023 after the end of K-12 COVID testing contracts.

• Q4 2024 adjusted EBITDA was negative $57 million, a significant improvement from negative $101 million in Q4 2023; full-year adjusted EBITDA was negative $293 million, up from negative $365 million in 2023.

• Q4 2024 net loss (GAAP) improved 49% year-over-year to $(108) million; full-year net loss was $(547) million, a 39% improvement.

Outlook and guidance

• FY 2025 revenue guidance: $160–$180 million, with Cell Engineering at $110–$130 million and Biosecurity at $50 million+.

• Path to adjusted EBITDA break-even by end of 2026, with further cost reductions and potential upside from new tools offerings.

• Targeting annualized run-rate cost savings of $250 million by Q3 2025.